Ozempic alternatives — when to consider switching
If Ozempicisn't working as expected, isn't covered by your insurance, side effects are intolerable, or you want to try something with different efficacy profile, several FDA-approved alternatives exist within the GLP-1 family. This page compares each on efficacy, dosing schedule, cost, and switching considerations.
The GLP-1 family — your alternatives
Single GLP-1 receptor agonists
- Semaglutide (Ozempic for diabetes, Wegovy for weight loss, Rybelsus oral) — Novo Nordisk
- Liraglutide (Victoza for diabetes, Saxenda for weight loss) — Novo Nordisk
- Dulaglutide (Trulicity for diabetes) — Eli Lilly
- Exenatide (Byetta, Bydureon for diabetes) — AstraZeneca
Dual GIP/GLP-1 receptor co-agonists
- Tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) — Eli Lilly
Efficacy comparison — at-a-glance
Mean body-weight reduction in pivotal trials (higher = more weight loss):
- Tirzepatide (Mounjaro / Zepbound): ~22.5% at 72 weeks (SURMOUNT-1)
- Semaglutide 2.4mg (Wegovy): ~14.9% at 68 weeks (STEP-1)
- Semaglutide 1.0mg (Ozempic): ~6-8% at 68 weeks (varies by trial)
- Liraglutide 3.0mg (Saxenda): ~8% at 56 weeks (SCALE)
- Dulaglutide (Trulicity): ~3-5% (not a weight-loss-specific indication)
Dosing frequency comparison
- Once weekly: Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Bydureon
- Once daily: Saxenda, Victoza
- Twice daily: Byetta (older formulation)
- Oral (daily): Rybelsus
Switching considerations
Switching within the same active ingredient
Switching between Mounjaro ↔ Zepbound (both tirzepatide), or Ozempic ↔ Wegovy (both semaglutide), or Victoza ↔ Saxenda (both liraglutide), is straightforward because the active ingredient is identical. The main differences are dose (Wegovy goes to 2.4mg vs Ozempic max ~2mg) and labeled indication (weight loss vs diabetes). Prescribers can transition without dose reset.
Switching between different active ingredients
Switching from semaglutide → tirzepatide (or vice versa), or to/from liraglutide, typically requires restarting titrationfrom the new drug's lowest dose. This is because:
- Different doses correspond to different molecular potencies
- Tolerability differs — even if you tolerated full-dose semaglutide, you may need to titrate up on tirzepatide
- Insurance coverage often requires fresh prior authorization for the new drug
Switching to compounded versions
Some patients switch from FDA-brand Ozempic to a compounded version of the same active ingredient for cost reasons. Important caveats:
- Compounded versions are not FDA-approved formulations
- Dose conversions may not be 1:1 — verify with the compounding pharmacy
- Quality varies by compounding pharmacy (use state-licensed 503A or FDA-registered 503B)
- Following 2025 FDA shortage resolution, the legal basis for compounding GLP-1s has narrowed
See our medical disclaimer for full compounded GLP-1 risk discussion.
Cost comparison
Cash-pay prices vary widely. Approximate ranges per month:
- Compounded semaglutide / tirzepatide via partner: $199–$399
- FDA-brand via telehealth partner subscription: $349–$899
- FDA-brand via manufacturer direct (LillyDirect / NovoCare): varies — often discounted
- Retail without insurance: $900–$1,300+
FAQ about Ozempic alternatives
How do I know if I should switch?
Common reasons to consider switching: insufficient weight loss at maximum tolerated dose, intolerable side effects despite slow titration, cost / insurance changes, or your prescriber recommends a switch based on your individual response. Always discuss with your prescriber rather than self-switching.
Can I take two GLP-1s at the same time?
No. Combining two GLP-1 receptor agonists provides no additional benefit and dramatically increases side-effect risk. Standard practice is to switch from one to another, not combine.
What if all GLP-1s don't work for me?
GLP-1s help most but not all patients. Alternatives outside the GLP-1 class include older medications (phentermine, naltrexone-bupropion combination, topiramate, orlistat), and for severe obesity, bariatric surgery. Discuss with your prescriber.
Compare specific pairs head-to-head on our comparison hub. Full medical disclaimer.